ANIK PE Ratio & Valuation,Is ANIK Overvalued

ANIK Relative Valuation

ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIK is overvalued; if below, it's undervalued.

Historical Valuation

Anika Therapeutics Inc (ANIK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 201.59. The fair price of Anika Therapeutics Inc (ANIK) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：9.57

Fair

53.17

16.18

EV/EBITDA

Anika Therapeutics Inc. (ANIK) has a current EV/EBITDA of 16.18. The 5-year average EV/EBITDA is -49.78. The thresholds are as follows: Strongly Undervalued below -844.18, Undervalued between -844.18 and -446.98, Fairly Valued between 347.43 and -446.98, Overvalued between 347.43 and 744.63, and Strongly Overvalued above 744.63. The current Forward EV/EBITDA of 16.18 falls within the Historic Trend Line -Fairly Valued range.

-8.48

EV/EBIT

Anika Therapeutics Inc. (ANIK) has a current EV/EBIT of -8.48. The 5-year average EV/EBIT is -255.16. The thresholds are as follows: Strongly Undervalued below -1923.27, Undervalued between -1923.27 and -1089.21, Fairly Valued between 578.89 and -1089.21, Overvalued between 578.89 and 1412.94, and Strongly Overvalued above 1412.94. The current Forward EV/EBIT of -8.48 falls within the Historic Trend Line -Fairly Valued range.

1.19

Anika Therapeutics Inc. (ANIK) has a current PS of 1.19. The 5-year average PS is 2.45. The thresholds are as follows: Strongly Undervalued below 0.76, Undervalued between 0.76 and 1.61, Fairly Valued between 3.30 and 1.61, Overvalued between 3.30 and 4.15, and Strongly Overvalued above 4.15. The current Forward PS of 1.19 falls within the Undervalued range.

0.00

P/OCF

Anika Therapeutics Inc. (ANIK) has a current P/OCF of 0.00. The 5-year average P/OCF is 150.49. The thresholds are as follows: Strongly Undervalued below -806.23, Undervalued between -806.23 and -327.87, Fairly Valued between 628.86 and -327.87, Overvalued between 628.86 and 1107.22, and Strongly Overvalued above 1107.22. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

66.63

P/FCF

Anika Therapeutics Inc. (ANIK) has a current P/FCF of 66.63. The 5-year average P/FCF is 6.11. The thresholds are as follows: Strongly Undervalued below -595.24, Undervalued between -595.24 and -294.57, Fairly Valued between 306.78 and -294.57, Overvalued between 306.78 and 607.45, and Strongly Overvalued above 607.45. The current Forward P/FCF of 66.63 falls within the Historic Trend Line -Fairly Valued range.

Anika Therapeutics Inc (ANIK) has a current Price-to-Book (P/B) ratio of 0.94. Compared to its 3-year average P/B ratio of 1.39 , the current P/B ratio is approximately -32.27% higher. Relative to its 5-year average P/B ratio of 1.52, the current P/B ratio is about -38.10% higher. Anika Therapeutics Inc (ANIK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.39% , the current FCF yield is about -100.00% lower.

0.94

P/B

Median3y

1.39

Median5y

1.52

0.47

FCF Yield

Median3y

-1.35

Median5y

-0.39

Competitors Valuation Multiple

The average P/S ratio for ANIK's competitors is , providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -28.22%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ANIK decreased by 41.86% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.64 to -9.67.

The secondary factor is the Revenue Growth, contributed -28.22%to the performance.

Overall, the performance of ANIK in the past 1 year is driven by P/E Change. Which is more unsustainable.

-28.22%

38.75M → 27.82M

Revenue Growth

-85.22%

-77.20 → -11.41

Margin Expansion

71.58%

-5.64 → -9.67

P/E Change

-41.86%

16.46 → 9.57

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Anika Therapeutics Inc (ANIK) currently overvalued or undervalued?

What is Anika Therapeutics Inc (ANIK) fair value?

ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Anika Therapeutics Inc (ANIK) is between NaN to NaN according to relative valuation methord.

How does ANIK's valuation metrics compare to the industry average?

What is the current P/B ratio for Anika Therapeutics Inc (ANIK) as of Dec 16 2025?

As of Dec 16 2025, Anika Therapeutics Inc (ANIK) has a P/B ratio of 0.94. This indicates that the market values ANIK at 0.94 times its book value.

What is the current FCF Yield for Anika Therapeutics Inc (ANIK) as of Dec 16 2025?

As of Dec 16 2025, Anika Therapeutics Inc (ANIK) has a FCF Yield of 0.00%. This means that for every dollar of Anika Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Anika Therapeutics Inc (ANIK) as of Dec 16 2025?

As of Dec 16 2025, Anika Therapeutics Inc (ANIK) has a Forward P/E ratio of 53.17. This means the market is willing to pay $53.17 for every dollar of Anika Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Anika Therapeutics Inc (ANIK) as of Dec 16 2025?

As of Dec 16 2025, Anika Therapeutics Inc (ANIK) has a Forward P/S ratio of 0.00. This means the market is valuing ANIK at $0.00 for every dollar of expected revenue over the next 12 months.

ANIK Valuation